Decades before people with Alzheimer’s disease develop memory loss and confusion, their brains become dotted with plaques made of a sticky protein – called amyloid beta – that is thought to contribute to the disease and its progression.
Currently, the only way to detect amyloid beta in the brain is via PET scanning, which is expensive and not widely available, or a spinal tap, which is invasive and requires a specialized medical procedure. But now, a study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their brains or cerebrospinal fluid.
Ideally, a blood-based screening test would identify people who have started down the path toward Alzheimer’s years before they could be diagnosed based on symptoms.
“Our results demonstrate that this amyloid beta blood test can detect if amyloid has begun accumulating in the brain,” said Randall J. Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology and the study’s senior author. “This is exciting because it could be the basis for a rapid and inexpensive blood screening test to identify people at high risk of developing Alzheimer’s disease.”
The findings will be announced July 19 at the Alzheimer’s Association International Conference in London and published online in the journal Alzheimer’s and Dementia.
As the brain engages in daily tasks, it continually produces and clears away amyloid beta. Some is washed into the blood, and some floats in the cerebrospinal fluid, for example. If amyloid starts building up, though, it can collect into plaques that stick to neurons, triggering neurological damage.
A blood test would be cheaper and less invasive than PET scans or spinal taps, but previous studies have found that measures of total levels of amyloid beta in the blood don’t correlate with levels in the brain.
So Bateman and colleagues measured blood levels of three amyloid subtypes – amyloid beta 38, amyloid beta 40 and amyloid beta 42 — using highly precise measurement by mass spectrometry to see if any correlated with levels of amyloid in the brain.
The researchers studied 41 people ages 60 and older. Twenty-three were amyloid-positive, meaning they had signs of cognitive impairment. PET scans or spinal taps in these patients also had detected the presence of amyloid plaques in the brain or amyloid alterations in the cerebrospinal fluid. The researchers also measured amyloid subtypes in 18 people who had no buildup of amyloid in the brain.
To measure amyloid levels, production and clearance over time, the researchers drew 20 blood samples from each person over a 24-hour period. They found that levels of amyloid beta 42 relative to amyloid beta 40 were consistently 10 to 15 percent lower in the people with amyloid plaques.
“Amyloid plaques are composed primarily of amyloid beta 42, so this probably means that it is being deposited in the brain before moving into the bloodstream,” Bateman said.
“The differences are not big, but they are highly consistent,” he explained. “Our method is very sensitive, and particularly when you have many repeated samples as in this study — more than 500 samples overall — we can be highly confident that the difference is real. Even a single sample can distinguish who has amyloid plaques.”
By averaging the ratio of amyloid beta 42 to amyloid beta 40 over each individual’s 20 samples, the researchers could classify people accurately as amyloid-positive or -negative 89 percent of the time. On average, any single time point was also about 86 percent accurate.
Amyloid plaques are one of the two characteristic signs of Alzheimer’s disease; the other sign is the presence of tangles of a brain protein known as tau. David Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of the Department of Neurology at the School of Medicine, is developing a blood-based test for tau that could complement the amyloid test.
“If we had a blood test for tau as well, we could combine them to get an even better idea of who is most at risk of developing Alzheimer’s disease,” Bateman said. “That would be a huge step forward in our ability to predict, and maybe even prevent, Alzheimer’s disease.”
The Latest on: Alzheimer’s
- Obituary: Mary Folletton January 23, 2021 at 10:09 pm
Mary Follett, 83, passed away Jan. 22, 2021 at the Alzheimers Care Unit in Gardiner where she has resided for the last two years. She had lived in Windsor for the past 55 years. Mary was born July 30, ...
- Alzheimers Assoc. offers virtual resource fair for caregiverson January 20, 2021 at 12:27 pm
ATLANTA, Ga. (WALB) - The Alzheimer’s Association, Georgia Chapter is hosting a statewide Caregiver Resource Fair, a virtual three-hour program that will help Alzheimer’s and dementia ...
- Alzheimers Q&A: How do you have hope after an Alzheimer's diagnosi?on January 18, 2021 at 4:00 am
Alzheimer’s disease is a truly life-changing illness, not only for the person diagnosed but for their entire family as well.
- Alzheimer’s Awareness Month mitigates social isolation for caregiverson January 16, 2021 at 11:38 pm
2:18 Alzheimers Society of B.C. connects virtually with caregivers to mitigate isolation Naomi Mison has dedicated her life to helping others after her mother was diagnosed with Frontotemporal ...
- Cognito Therapeutics Receives FDA Breakthrough Device Designation for Next-Generation Digital Therapeutic in Alzheimers Diseaseon January 12, 2021 at 5:00 am
Cognito Therapeutics, a clinical-stage company leading the development of a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, announced today its lead product ...
- Alzheimers Q&A: What are the warning signs of Alzheimer's disease?on January 11, 2021 at 4:07 am
Alzheimer’s disease is a degenerative brain disorder that has no cure. There's no way to slow or stop its progression, and there's no proven way to prevent it. The disease is named after Dr ...
- Why the Alzheimers Society is still as important today as 40 years agoon January 10, 2021 at 2:19 pm
Our story began in 1979 with a small group of passionate and determined people who shared an ambition to make life better for carers of people with dementia. They united to improve care, set up ...
- ALZHEIMERS ANGEL CENTERon January 9, 2021 at 10:50 pm
Details and information displayed here were provided by this business and may not reflect its current status. We strongly encourage you to perform your own research when selecting a care provider.
- Alzheimers Treatment Market Analysis 2020-2027 by Latest Trends, Leading Key Players, Future Growth, Revenue Analysis, Demand Forecaston December 30, 2020 at 4:00 pm
The MarketWatch News Department was not involved in the creation of this content. Dec 31, 2020 (AmericaNewsHour) -- According to the Alzheimer's Association in 2020, an estimated 5.8 million ...
via Google News and Bing News